MIPI Alliance Expands Reach with New Automotive Working Group
The MIPI Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced the formation of the MIPI Automotive Working Group (AWG) to address the needs of the automotive ecosystem. The group is open to MIPI Contributor members.
As the number of sensors continues to increase in the automobile to support passive and active safety, infotainment, advanced driver assistance systems (ADAS) and autonomous driving systems, the need for interface specifications is apparent. Building upon the success of the MIPI Alliance Automotive Subgroup and Automotive Birds of a Feather (BoF) Group, the MIPI Board of Directors has approved the creation of the MIPI AWG.
“The approval of the MIPI Automotive Working Group marks a significant milestone for MIPI Alliance’s development activity,” said Joel Huloux, chairman of MIPI Alliance. “While MIPI’s focus is foremost on developing interface specifications for mobile devices, automakers already rely on MIPI’s industry-standard interfaces to enable a wide variety of applications. This additional focus on automotive is a natural extension to broaden MIPI specifications’ applicability.”
The first focus of the group will be to collaborate with other MIPI working groups on a new automotive physical layer specification for longer reach applications. This work will build upon the success of MIPI Alliance’s development of high-speed physical layer specifications that serve as essential interconnection in mobile and other devices. In addition, the group will look at other existing MIPI specifications and determine their adaptability to automotive use cases.
“We look forward to working with MIPI working groups and the MIPI Auto BoF to bring together automotive ecosystem requirements to support a high-speed serial data link,” said Matt Ronning, chair of the MIPI AWG. “MIPI’s Automotive Working Group will help align key interfaces for cameras, lidars, radars, displays and more with OEMs’ specific requirements in automotive. As new MIPI interfaces are developed, while rooted in mobile, they will now also have an eye toward automotive.”
“Standardization of all interfaces between subsystems, like surround sensors, and ECUs (electronic control units) is a prerequisite of modular concepts for automotive systems,” said Uwe Beutnagel-Buchner, vice chair of the MIPI AWG. “Additionally automotive systems stand to benefit from standardized interfaces to meet development, cost, testing and reliability requirements. Highly sensitive, mission-critical automotive applications also benefit from MIPI interfaces’ low electromagnetic interference (EMI), a capability that’s been proven in billions of mobile phones and other handheld devices.”
Join the MIPI Alliance Automotive Working Group
The MIPI AWG is seeking Contributor member participants to provide key input into current and future MIPI interface specifications. The Automotive Working Group will meet through regular teleconferences, as well as face-to-face sessions at MIPI member meetings.
To learn more about the AWG, visit: http://bit.ly/2Ffj075
The Auto BoF will remain in place to foster communication between the AWG and the automotive ecosystem. Qualified experts from original equipment manufacturers (OEMs), tier-one suppliers, component suppliers and related are encouraged to join the existing MIPI Auto BoF, which is open to both MIPI members and nonmembers. To learn more and join the group visit: http://bit.ly/2FcVRX9
Additionally, MIPI Alliance will host a webinar “MIPI Alliance Extends Interface Standards to Support the Automotive Market,” on April 4, 2018, at 8:00 am PDT, 11 am EDT. To register, go to: http://bit.ly/2Fdmnzu
Join MIPI at ADAS Sensors 2018
MIPI Alliance is a sponsor the 3rd Annual ADAS Sensors Conference & Exhibition on April 4-5, 2018, in Detroit, Michigan. Learn more at: http://www.adassensors.com/index.html
To discover more about MIPI Alliance and to connect with its social networks, follow its Twitter page, join its LinkedIn group and like its Facebook page. To join MIPI Alliance, use the Join MIPI link on the organization’s site.
About MIPI Alliance
MIPI Alliance (MIPI) develops interface specifications for mobile and mobile-influenced industries. There is at least one MIPI specification in every smartphone manufactured today. Founded in 2003, the organization has 300 member companies worldwide and 13 active working groups delivering specifications within the mobile ecosystem. Members of the organization include handset manufacturers, device OEMs, software providers, semiconductor companies, application processor developers, IP tool providers, test and test equipment companies, as well as camera, tablet and laptop manufacturers. For more information, please visit www.mipi.org.
MIPI® is a registered trademark owned by MIPI Alliance. All other trademarks cited are the property of their respective owners.
Interprose for MIPI Alliance
Lisa McCausland, +1 303-888-2137
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i